98 related articles for article (PubMed ID: 10390009)
1. The significance of measuring monocyte tissue factor activity in patients with breast and colorectal cancer.
Lwaleed BA; Chisholm M; Francis JL
Br J Cancer; 1999 Apr; 80(1-2):279-85. PubMed ID: 10390009
[TBL] [Abstract][Full Text] [Related]
2. Monocyte tissue factor levels in cancer patients.
Lwaleed BA; Francis JL; Chisholm M
Saudi Med J; 2000 Aug; 21(8):722-9. PubMed ID: 11423883
[TBL] [Abstract][Full Text] [Related]
3. Urinary tissue factor levels in patients with breast and colorectal cancer.
Lwaleed BA; Chisholm M; Francis JL
J Pathol; 1999 Feb; 187(3):291-4. PubMed ID: 10398081
[TBL] [Abstract][Full Text] [Related]
4. Procoagulant activity in whole blood from patients with breast and colorectal cancer.
Parmar J; Taylor I; Roath S; Francis J
Blood Coagul Fibrinolysis; 1990 Jun; 1(2):127-32. PubMed ID: 2130924
[TBL] [Abstract][Full Text] [Related]
5. Monocyte tissue factor levels in patients with urological tumours: an association between tumour presence and progression.
Lwaleed BA; Francis JL; Chisholm M
BJU Int; 1999 Mar; 83(4):476-82. PubMed ID: 10210574
[TBL] [Abstract][Full Text] [Related]
6. Tissue factor assays as diagnostic tools for cancer? Correlation between urinary and monocyte tissue factor activity.
Lwaleed BA; Francis JL; Chisholm M
J Hematother Stem Cell Res; 1999 Dec; 8(6):659-68. PubMed ID: 10645774
[TBL] [Abstract][Full Text] [Related]
7. The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer.
Al Sarakbi W; Mokbel R; Salhab M; Jiang WG; Reed MJ; Mokbel K
Anticancer Res; 2006; 26(6C):4985-90. PubMed ID: 17214375
[TBL] [Abstract][Full Text] [Related]
8. Urinary tissue factor levels in patients with bladder and prostate cancer.
Lwaleed BA; Francis JL; Chisholm M
Eur J Surg Oncol; 2000 Feb; 26(1):44-9. PubMed ID: 10718179
[TBL] [Abstract][Full Text] [Related]
9. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
[TBL] [Abstract][Full Text] [Related]
10. Monocytes and plasma tissue factor levels in normal individuals and patients with deep venous thrombosis of the lower limbs: potential diagnostic tools?
Vieira LM; Dusse LM; Fernandes AP; Martins-Filho OA; de Bastos M; Ferreira MF; Cooper AJ; Lwaleed BA; Carvalho MG
Thromb Res; 2007; 119(2):157-65. PubMed ID: 16527335
[TBL] [Abstract][Full Text] [Related]
11. Thyroid autoimmunity occurs more frequently in women with breast cancer compared to women with colorectal cancer and controls but it has no impact on relapse-free and overall survival.
Jiskra J; Barkmanova J; Limanova Z; Lánská V; Smutek D; Potlukova E; Antosova M
Oncol Rep; 2007 Dec; 18(6):1603-11. PubMed ID: 17982651
[TBL] [Abstract][Full Text] [Related]
12. Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer.
Tsai WS; Changchien CR; Yeh CY; Chen JS; Tang R; Chiang JM; Hsieh PS; Fan CW; Wang JY
Dis Colon Rectum; 2006 Jun; 49(6):883-94. PubMed ID: 16741643
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of protein Z detection in patients with malignant tumors].
Shang Y; Pan XY; Ding CP; Yang XM; Cai XY; Ding Y; Zhang RL
Ai Zheng; 2005 Sep; 24(9):1144-7. PubMed ID: 16159443
[TBL] [Abstract][Full Text] [Related]
14. Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer.
Jiang WG; Douglas-Jones AG; Mansel RE
Prostaglandins Leukot Essent Fatty Acids; 2006 Feb; 74(2):125-34. PubMed ID: 16364620
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients.
Ottaiano A; Franco R; Aiello Talamanca A; Liguori G; Tatangelo F; Delrio P; Nasti G; Barletta E; Facchini G; Daniele B; Di Blasi A; Napolitano M; Ieranò C; Calemma R; Leonardi E; Albino V; De Angelis V; Falanga M; Boccia V; Capuozzo M; Parisi V; Botti G; Castello G; Vincenzo Iaffaioli R; Scala S
Clin Cancer Res; 2006 May; 12(9):2795-803. PubMed ID: 16675573
[TBL] [Abstract][Full Text] [Related]
16. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival.
Benoy IH; Salgado R; Van Dam P; Geboers K; Van Marck E; Scharpé S; Vermeulen PB; Dirix LY
Clin Cancer Res; 2004 Nov; 10(21):7157-62. PubMed ID: 15534087
[TBL] [Abstract][Full Text] [Related]
17. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
18. Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer.
Horiuchi S; Yamamoto H; Min Y; Adachi Y; Itoh F; Imai K
J Pathol; 2003 Aug; 200(5):568-76. PubMed ID: 12898592
[TBL] [Abstract][Full Text] [Related]
19. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group.
Werther K; Christensen IJ; Brünner N; Nielsen HJ
Eur J Surg Oncol; 2000 Nov; 26(7):657-62. PubMed ID: 11078612
[TBL] [Abstract][Full Text] [Related]
20. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
Foekens JA; Peters HA; Grebenchtchikov N; Look MP; Meijer-van Gelder ME; Geurts-Moespot A; van der Kwast TH; Sweep CG; Klijn JG
Cancer Res; 2001 Jul; 61(14):5407-14. PubMed ID: 11454684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
